Top

COVID-19 Vaccination in Pregnant and Breastfeeding Women and those planning pregnancy


Updated Friday 22 April 2022


The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) acknowledges the risk posed to the community, healthcare workers, and all patients, due to the COVID-19 pandemic. RANZCOG also recognises our responsibility to respond to this situation as a large organisation, and also as a medical college, and health leader.

The College respects the role of government, health departments and health administrators in coordinating a national response in Australia and New Zealand. The purpose of this communiqué is to provide updated advice on the issue of vaccination for pregnant and breastfeeding women, and those planning pregnancy in Australia, in line with updated advice from The Australian Technical Advisory Group on Immunisation (ATAGI). 

RANZCOG advice aligns with that issued by ATAGI.
 

Key points

 
  • Pregnant women have a higher risk of severe illness from COVID-19. Their babies also have a higher risk of being born prematurely.
  • COVID-19 vaccination significantly reduces the risk of becoming infected with COVID-19. Vaccination also reduces your risk of transmitting the virus to others, including to infants. 
  • COVID-19 vaccination may provide indirect protection to babies by transferring antibodies through the placenta (for pregnant women) or through breastmilk (for breastfeeding women).
  • Pregnant women in Australia are a priority group for COVID-19 vaccination and should be routinely offered the Pfizer vaccine (Comirnaty) or Moderna (Spikevax) at any stage of pregnancy. 
  • Pregnant women in Aotearoa New Zealand are a priority group for COVID-19 vaccination and should be routinely offered the Pfizer vaccine (Comirnaty) as this is the only vaccine currently approved for pregnant women in New Zealand.
  • Pfizer (Comirnaty) and Moderna (Spikevax) are mRNA vaccines. Global evidence has shown that the Pfizer and Moderna vaccines are safe for pregnant women.
  • Novavax COVID-19 vaccine can also be used in pregnancy.  While there are no immunogenicity or safety data, there are no theoretical safety concerns relating to its use in pregnancy, since the Novavax COVID-19 vaccine, like other COVID-19 vaccines, is not a live vaccine.
  • There is no evidence of increased risk of miscarriage or teratogenic risk with mRNA or viral vector vaccines.
  • Women who are trying to become pregnant do not need to delay vaccination or avoid becoming pregnant after vaccination. 
  • Booster injections for pregnant women are suggested 3 months after the second dose and are vital for protection against the Omicron strains BA.1 and BA.2.
  • All healthcare workers, including midwives and doctors, are encouraged to be vaccinated, to protect themselves, pregnant women, and their babies. The vaccine does not cause “shedding” and vaccinated people are far less likely to transmit COVID-19.
 


What are the current recommendations for COVID-19 vaccine in pregnant women? 


Pregnant women are a priority group for COVID-19 vaccination and should be routinely offered Pfizer mRNA vaccine (Cominarty) [or Moderna (Spikevax) in Australia] at any stage of pregnancy. 

Pregnant women with COVID-19 have a higher risk of severe illness compared to non-pregnant women with COVID-19 of the same age. This includes an increased risk of:
-    hospitalisation
-    admission to an intensive care unit
-    invasive ventilation. 

COVID-19 during pregnancy also increases the risk of complications for the baby including a higher risk of stillbirth and of being born prematurely.

Vaccination is the best way to reduce these risks.

Pregnant women should get vaccinated and continue to follow the current guidelines to prevent the spread of COVID-19 after they are vaccinated. Vaccination significantly reduces the risk of becoming infected with COVID. Vaccination also reduces your risk of transmitting the virus to others, including your baby. Everyone should continue with hand hygiene, masks where social distancing cannot be maintained, testing when symptoms are present and isolation, when appropriate.
 


When is the best time to have a COVID-19 vaccine if I am pregnant?


It is recommended to have a COVID-19 vaccine as soon as you are offered one.

Pfizer (Cominarty) and Moderna (Spikevax) are mRNA vaccines and can be given at any stage of pregnancy. Two doses of Pfizer or Moderna vaccine, 3-6 weeks apart, provides good protection against COVID-19, including against the Delta strain. With the advent of the Omicron strain it is recommended that a booster dose is administered 3 months after the second dose of the vaccine. Current approved Covid-19 vaccines have been shown to be similarly effective against both Omicron BA.1 and BA.2 when a booster dose has been administered.

Covid-19 vaccines can be given at the same time as an influenza vaccine. The administration of other types of vaccines (whooping cough vaccine etc.) with a COVID-19 vaccine is not recommended. The minimum interval time between a COVID-19 vaccine and any vaccine other than the influenza vaccine, is 7 days.

All medical advice should be patient-centred and take into account each individual’s personal considerations and preferences. 

Please note: Eligibility for vaccination is determined by the Australian Government and the New Zealand Ministry of Health, and local jurisdictions, and is not within the authority of RANZCOG.

Aotearoa New Zealand Advice:
  • Three (3) COVID-19 vaccines are currently available in New Zealand: Pfizer (Comirnaty); AstraZeneca (Vaxzevria) and Novavax (Nuvaxovid). 
  • Pregnant women in Aotearoa New Zealand are a priority group for COVID-19 vaccination and should be routinely offered the Pfizer vaccine (Comirnaty) as the only vaccine currently approved for pregnant women in New Zealand.
  • New Zealand Government Ministry of Health
  • Immunisation Advisory Centre

Australian Advice:
  • Four (4) COVID-19 vaccines are approved in Australia: Pfizer (Comirnaty); Moderna (Spikevax); AstraZeneca (Vaxzevria) and Novavax (Nuvaxovid). 
  • Pregnant women in Australia are a priority group for COVID-19 vaccination and should be routinely offered the Pfizer vaccine (Comirnaty) or Moderna (Spikevax) at any stage of pregnancy. 
  • Everyone in Australia aged 5 years and over is eligible for a free COVID-19 vaccination. Use the Australian Government Eligibility Checker to arrange an appointment. A national coronavirus Hotline (1800 020 080) is available to find relevant vaccination clinics.

Please note: When using the eligibility checker, pregnant women should tick ‘no’ to AstraZeneca and progress to the end.


Recommendations for women who have already received a dose of AstraZeneca Vaccine.


Pregnant women who have already received a first dose of AstraZeneca vaccine can receive either the Pfizer vaccine or Moderna or the AstraZeneca vaccine for their second dose within the recommended time periods.
  • Research has shown that mRNA vaccines (e.g., Pfizer or Moderna) are safe for pregnant women.
  • There is less available data on the safety of viral vector vaccines (e.g., Astra Zeneca) in pregnancy, hence the current recommendation for pregnant women to receive mRNA vaccines (Pfizer or Moderna). 


Other treatments in pregnancy

Pregnant women should continue to receive pertussis and influenza vaccination during pregnancy, noting the advice to space vaccine injections by at least one week.

The administration of Anti-D should continue as per usual indications and timing is not affected by vaccination.


What are the recommendations for women planning pregnancy?


Women who are trying to become pregnant can receive either COVID-19 vaccines (Pfizer, Moderna, AstraZeneca or Novavax), as approved within their country. They do not need to delay vaccination or avoid becoming pregnant after vaccination.


What are the recommendations for breastfeeding women? 


Vaccination is recommended for breastfeeding women. They do not need to stop breastfeeding before or after vaccination. 

Either Pfizer, Moderna or AstraZeneca vaccines are considered safe for breastfeeding women. 

There are substantial data on the safe use of the Pfizer and Moderna vaccines in breastfeeding women. The mRNA in Pfizer or Moderna is rapidly broken down in the body and does not appear to pass into breastmilk. The viral vector in AstraZeneca cannot cause infection.

There is currently no immunogenicity or safety data for these groups with the Novavax vaccine. 

 

Further information


Further information can be found here

RANZCOG will continue to monitor available data and issue updated advice as evidence emerges. 

 

MyAus COVID-19 app


RANZCOG recognises the importance of ensuring multicultural communities throughout Australia have the information they need about the COVID-19 vaccination program, and would recommend members encourage their patients use the Migration Council Australia’s MyAus COVID-19 app.
 
The Council developed MyAus COVID-19 - a multilingual app for Australia’s culturally and linguistically diverse communities about COVID-19, its impact and available support.

MyAus COVID-19 app supports access to information in a user-friendly format, including via short animations. The app is supported by the Australian Government and is currently available in 29 community languages. Available for iPhones and Android.
 

Further research


The circumstances of the COVID-19 pandemic are unprecedented and knowledge is continually evolving. RANZCOG emphasises the importance of inclusion of pregnant and breastfeeding women in clinical trials of COVID-19 vaccines to develop evidence-based advice regarding safety and efficacy.
 

 

Disclaimer

Disclaimer

The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) is the lead body for women’s health in Australia and New Zealand and carries the responsibility for advice, dissemination of information and support of our members, our patients and the community during the Covid-19 pandemic.

The College respects the role of government, health departments and health administrators in coordinating a national response. Our public statements are made following consultation with officials, and medical experts, and with the understanding that the impacts of the pandemic are evolving, multifactorial and that action in one area will have intended, and unintended, effects on other areas.

RANZCOG will continue to provide information and advice that is the best available, to our knowledge. Given the recency of Covid-19 and the paucity of data, particularly in pregnancy, the accuracy of any advice may be rapidly superseded. We will endeavour to regularly update our communication as new information becomes available. Furthermore, RANZCOG will not comment on areas beyond our remit.

RANZCOG commentary on COVID-19 should be considered advisory, and not proscriptive, and all health workers, and the general public, should heed the advice of government and health authorities.
 

 

 

MEDIA CENTRE

News

New Zealand Budget 2022 statement

RANZCOG welcomes an Aotearoa New Zealand budget focussed on health.

22/05/2022

News

Call for clean energy by 2030

RANZCOG joins with other medical colleges in calling for clean energy by 2030 to protect health.

19/05/2022

News

Jony Berry

RANZCOG welcomes Jony Berry to the role of Aboriginal and Torres Strait Islander Health Advisor.

16/05/2022